XRAY
Price
$8.51
Change
-$0.02 (-0.23%)
Updated
Oct 13 closing price
Capitalization
1.85B
16 days until earnings call
Intraday BUY SELL Signals
XWEL
Price
$0.79
Change
-$0.05 (-5.95%)
Updated
Oct 13 closing price
Capitalization
7.7M
Intraday BUY SELL Signals
Interact to see
Advertisement

XRAY vs XWEL

XRAY vs XWEL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
XRAY vs. XWEL commentary
Oct 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XRAY is a Buy and XWEL is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
XRAY vs XWEL: Fundamental Ratings
XRAY
XWEL
OUTLOOK RATING
1..100
5664
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6575
P/E GROWTH RATING
1..100
812
SEASONALITY SCORE
1..100
904

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (2) in the Medical Specialties industry is somewhat better than the same rating for XWEL (49) in the Other Consumer Services industry. This means that XRAY’s stock grew somewhat faster than XWEL’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.

XRAY's SMR Rating (97) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.

XRAY's Price Growth Rating (65) in the Medical Specialties industry is in the same range as XWEL (75) in the Other Consumer Services industry. This means that XRAY’s stock grew similarly to XWEL’s over the last 12 months.

XWEL's P/E Growth Rating (2) in the Other Consumer Services industry is significantly better than the same rating for XRAY (81) in the Medical Specialties industry. This means that XWEL’s stock grew significantly faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XRAYXWEL
RSI
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
46%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
76%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
57%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
58%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 14, 2026
Stock price -- (XRAY: $8.51 vs. XWEL: $0.84)
Brand notoriety: XRAY and XWEL are both not notable
XRAY represents the Pharmaceuticals: Other, while XWEL is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: XRAY: 93% vs. XWEL: 423%
Market capitalization -- XRAY: $1.85B vs. XWEL: $7.7M
XRAY [@Pharmaceuticals: Other] is valued at $1.85B. XWEL’s [@Medical Specialties] market capitalization is $7.7M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $146.54B. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.89B. The average market capitalization across the [@Medical Specialties] industry is $20.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XRAY’s FA Score shows that 1 FA rating(s) are green while XWEL’s FA Score has 1 green FA rating(s).

  • XRAY’s FA Score: 1 green, 4 red.
  • XWEL’s FA Score: 1 green, 4 red.
According to our system of comparison, XWEL is a better buy in the long-term than XRAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XRAY’s TA Score shows that 5 TA indicator(s) are bullish while XWEL’s TA Score has 5 bullish TA indicator(s).

  • XRAY’s TA Score: 5 bullish, 4 bearish.
  • XWEL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XWEL is a better buy in the short-term than XRAY.

Price Growth

XRAY (@Pharmaceuticals: Other) experienced а -0.18% price change this week, while XWEL (@Medical Specialties) price change was +3.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.14%, and the average quarterly price growth was +7.32%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.57%. For the same industry, the average monthly price growth was +1.43%, and the average quarterly price growth was +38.17%.

Reported Earning Dates

XRAY is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-1.23% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Medical Specialties (-3.57% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
XRAY
Daily Signal:
Gain/Loss:
XWEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLMN9.210.44
+5.02%
Bloomin' Brands
FIS35.200.94
+2.74%
Fidelity National Information Services
PLNT47.45-0.44
-0.92%
Planet Fitness
COOK49.37-2.09
-4.06%
Traeger
EEIQ4.96-0.22
-4.25%
EpicQuest Education Group International Limited

XWEL and

Correlation & Price change

A.I.dvisor tells us that XWEL and LUCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and LUCY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XWEL
1D Price
Change %
XWEL100%
-6.02%
LUCY - XWEL
29%
Poorly correlated
-3.43%
DRIO - XWEL
28%
Poorly correlated
+2.21%
XRAY - XWEL
23%
Poorly correlated
-0.29%
NVCR - XWEL
22%
Poorly correlated
-2.85%
MBAI - XWEL
21%
Poorly correlated
-10.03%
More